Early Registration Is Open for #ISLB25!
Register by October 10, 2025, to take advantage of discounted rates. Full In-Person Registration Includes access to all Scientific Sessions (except ticketed sessions), entry to the Exhibition Hall, and more!
Register now at 2025.islb.info/lrdo
🩸🚀 New Insights in Liquid Biopsy! 🧬
The ISLB has just published a perspective article about Minimal requirement for ctDNA analysis.
🔗 Read the full article here
www.journalofliquidbiopsy.com/article/S295...
🚨Excited to represent the @islb.info at #ASCO25!
Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities!
Got questions about the society? We’ve got answers. Come to connect!🩸
@ascocancer.bsky.social @christianrolfo.bsky.social @rolfolab.bsky.social
Very honored of this important recognition in my born country. Blessed to share this special moment with my family, friends and great colleagues from Argentina 🇦🇷 looking forward to continue working with @UBAonline from OSU @OhioStateMedOnc ! Thanks to all my team @rolfolab.bsky.social
5/5
Both TBx & LBx are suitable & complementary for METex14 skipping detection.
✅LBx Pros: Minimally invasive, rapid, feasible for ill patients/inaccessible tumors, boosts enrollment
❌ LBx Cons: Can have lower sensitivity (false negatives) with low ctDNA shedding
4/5
Further analysis: Among TBx-positive patients with matched LBx results, those who were LBx-negative showed trends for longer DOR, PFS, and OS compared to those who were also LBx-positive. (Fig3)
3/5
Why the difference in time-dependent outcomes? LBx-positive patients had:
➡️ Higher baseline radiographic tumor burden
➡️ More extensive disease
➡️ Worse baseline health-related quality of life & symptoms.
While ORRs were similar (TBx-pos 54.3% vs. LBx-pos 51.7%), time-dependent outcomes trended shorter in LBx-positive patients. 📉 mPFS: 13.7 mo (TBx) vs. 8.9 mo (LBx). 📉 Median OS: 22.9 mo (TBx) vs. 17.6 mo (LBx)
New research from the #VISION trial of #tepotinib in #NSCLC with #METex14 skipping highlights key differences when patients are identified by LBxvs TBx.
➡️ #Tepotinib showed robust efficacy regardless of biopsy type
@christianrolfo.bsky.social @oncoalert.bsky.social
Visit at #AACR25 the poster by Dr. Eswar Shankar on “Synergistic Inhibition of TNBC via EZH2 inhibition and D1 Receptor Agonism”
@OSUCCC_James
@osuwexmed.bsky.social
@christianrolfo.bsky.social
@theaacr.bsky.social
pbs.twimg.com/media/Gpay9i...
Super excited to share the review I wrote with Carolina Reduzzi published in the Journal of Liquid Biopsy on the transformative impact of LB in oncology! 🩸🔬
LB is reshaping cancer care 💥
Check it out 👉 pubmed.ncbi.nlm.nih.gov/40255897/
@islb.info @christianrolfo.bsky.social @rolfolab.bsky.social
Congrats Roberto! And welcome to @rolfolab.bsky.social !!!
Day 3 at #TexasLung25 diving into diagnostics, #MRD, and #LiquidBiopsy with an outstanding faculty! 🩸🔬
Learning from the best: @christianrolfo.bsky.social @davidgandera @WadeIams @osucccjames.bsky.social @rolfolab.bsky.social
Exciting discussions shaping the future of #lungcancer testing! 📚
Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅
Grateful for the chance to meet with exceptional people 👐
@stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social
Navigating the future of #LiquidBiopsy with @christianrolfo.bsky.social at #poles25
From screening to resistance tracking—MRD is reshaping how we detect, treat, and monitor cancer.
Tissue vs liquid? It’s not a battle—it’s a partnership.
@rolfolab.bsky.social @islb.info @oncoalert.bsky.social
As always, an insightful presentation by @UmbertoMalapelle
➡️ "From single gene testing to CGP." 🔬✨
at #ELCC25 @myesmo.bsky.social
We must continue this path to improve treatment selection!
@islb.info #precisiononcology #lungcancer
⬇️ Key message
Today, I had the pleasure of presenting to the @MtSinaiASCOOSIG on the role of #liquidbiopsy in clinical practice and #precisiononcology! ❤️ An incredibly dynamic and engaging group! Great discussions and insights!
@osucccjames.bsky.social @rolfolab.bsky.social @christianrolfo.bsky.social
@unige
📢 Exciting update in the field of liquid biopsy! A new editorial highlights the essential role of the International Society of Liquid Biopsy (ISLB) in establishing quality framework for LB clinical implementation. 🧬🩸
Read more: doi.org/10.1016/j.crit…
#LiquidBiopsy
@christianrolfo.bsky.social
🚨 Out in @natrevclinoncol.bsky.social
📌ctDNA helps uncover resistance mechanisms
📌Standardized protocols are crucial for improving applications
📌ctDNA + tissue provides a more comprehensive view
nature.com/articles/s41...
@christianrolfo.bsky.social @osucccjames.bsky.social
Don’t miss this chance to contribute!
Great opportunity to gain valuable insights into METex14 skipping NSCLC! 🎦
Congratulations Roberto! Well deserved! @osucccjames.bsky.social
The HER2 protein is becoming a crucial target not only in breast cancer but also in other tumor subtypes. 🔬✨ Super experts discuss the role of IHC in #lungcancer and #ovariancancer!
@christianrolfo.bsky.social @rolfolab.bsky.social
@osucccjames.bsky.social
#HER2 #IHC #Targettherapy
✨ Insightful presentation by @manelesteller.bsky.social from
@carrerasijc.bsky.social at @osuwexmed.bsky.social
Starting from #epigenetics to #spatialtranscriptomics, unlocking a deeper understanding of tumor biology and cancer treatment! 🔬🧬💊
@christianrolfo.bsky.social @rolfolab.bsky.social
⏱️ To-do list for today: Tune in to the live webinar by
@iaslc.bsky.social covering key highlights from the 2024 Hot Topic in Basic & Translational Science Conference! 🔬🧬 Don't miss out on the latest breakthroughs!
@christianrolfo.bsky.social @rolfolab.bsky.social
www.iaslc.org/meetings-web...
Amazing group of medical oncologists that I am privileged to work with every day and call friends @stoverlab.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @quirogad.bsky.social @osucccjames.bsky.social
Don't miss the chance to dive into this interesting discussion on lung cancer with an incredible faculty! 🔎🫁💊
#lungcancer
#myESMO
#DeepDiveLungCancer
@christianrolfo.bsky.social @rolfolab.bsky.social
ow.ly/vbSt50UPrrS
🎯
The ISLB created this survey to understand how to improve the use of #liquidbiopsy in clinical oncology!
Don't miss the opportunity to shape the future of LB in cancer patients!! 🔥
@christianrolfo.bsky.social @robertoboreamd.bsky.social
🚨 Share your expertise in the liquid biopsy field! 🌟 Participate in the #ISLB survey to help shape strategies for improving #liquidbiopsies in clinical oncology.
Let’s advance precision care for medical oncologists together! 🩺🔬
@christianrolfo.bsky.social @rolfolab.bsky.social
When tissue is the issue!
Great presentation by @christianrolfo.bsky.social
at the XIII Molecular Cytopathology
We need to use liquid biopsy 🩸 and tissue together to get as many informations as possible! 🧬
@ohiostateuniversity @rolfolab.bsky.social @UmbertoMalapel1
@MariantoniaNac1
